![Pfizer Pfizer](https://static.packgene.com/wp-content/uploads/2023/10/Pfizer.jpg)
Pfizer (PFE.N), BioNTech (22UAy.DE) and biotech firm Promosome told a federal judge in San Diego, California that they have agreed to end Promosome’s lawsuit accusing the COVID-19 vaccine makers of infringing a patent related to messenger RNA technology.
The companies said in a court filing on Wednesday that Promosome would dismiss its case with prejudice, which means it cannot be refiled, and that Promosome had agreed not to bring future claims over the patent against Pfizer and its partner BioNTech. No financial terms were disclosed.
Representatives for Promosome and Pfizer did not immediately respond to requests for comment on Thursday. A representative for BioNTech’s attorneys declined to comment on the filing.
The agreement comes weeks after Promosome abandoned a related lawsuit against COVID-19 vaccine maker Moderna (MRNA.O).
San Diego and New York-based Promosome was formed to commercialize technology developed by biochemistry researchers at the Scripps Research Institute in La Jolla, California. Promosome sued Pfizer, BioNTech and Moderna in June, accusing the companies of copying its technology for making doses of mRNA small enough to use safely and effectively in the vaccines.
The lawsuits said that Promosome discussed its technology with representatives from Moderna and BioNTech between 2013 and 2016.
Promosome had asked the court for a share of royalties from the shots. Pfizer earned $37.8 billion last year from sales of its COVID-19 vaccine Comirnaty, while Moderna made $18.4 billion from its vaccine Spikevax.
Pfizer and BioNTech denied the allegations and claimed Promosome had withheld information from the U.S. Patent Office when applying for the patent that would have rendered it invalid.
The Promosome lawsuits were among several U.S. patent cases brought by biotech companies over the alleged misuse of their technology in the groundbreaking shots. Moderna filed a patent lawsuit against Pfizer and BioNTech last year that is still ongoing.
![GMP mRNA](https://static.packgene.com/wp-content/uploads/2023/07/13.jpg)
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
![](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
Plasmids GMP Services
Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE
![](https://static.packgene.com/wp-content/uploads/2023/01/10-2.png)
AAV GMP Services
Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
![aav icon](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
Technology Platforms
PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE